nad and glp-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms Action OF GLP-1 agonists In

Always consult a licensed healthcare professional before beginning any weight loss program or supplement regimenespecially if you have a medical condition or are taking medications

Ethics declarations Competing interests The author declares associations with the following companies: Astra-Zeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, NovoNordisk and Sanofi-Aventis (advisory board membership

Vangoitsenhoven R, Mathieu C, Van der Schueren B

Second, contrary to CVOTs on GLP-1 RAs that included T2DM patients with established cardiovascular disease or at high cardiovascular risk, tirzepatide trials randomized T2DM patients irrespective of presence of prior cardiovascular disease or cardiovascular risk factors, a fact that may account for the very low number of recorded MACE, and possibly for type II errors